Healthcare Burden of Probable and Proven Invasive Mucormycosis: A Multicenter Cost-of-Illness Analysis of Patients Treated in Tertiary Care Hospitals between 2003 – 2016
ConclusionOur study demonstrates the considerable healthcare burden of IM. The choice of an antifungal agent for treatment of IM had no impact on overall cost.
Source: Journal of Hospital Infection - Category: Infectious Diseases Source Type: research
More News: Chemotherapy | Epidemiology | Fungal Infections | Germany Health | Infectious Diseases | Study